Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Continuing professional development

From Mr K. Cooke

I commend Navjot Nannar for his comprehensive review of managing ankylosing spondylitis (AS). Having suffered from AS for nearly 40 years and with a wife who was a pharmacist until her retirement, I might be considered an expert patient.

The diagnosis of AS used to be notoriously slow but the symptoms are now more readily recognised. Confusingly, different AS patients can show different selections of symptoms and the severity of each can vary widely.

I have been taking the newly approved (for AS) antitumour necrosis factor agent adalimumab by self-injection and have just passed the 12-week review date. It has substantially improved my condition and brought great benefits to my lifestyle.

Dr Nannar descibes the association of AS with a genetic marker, HLA B27. Readers might like to know that other genetic factors have also been identified and that research continues into their relevance.

Ken Cooke
Ilkley, West Yorkshire

Citation: The Pharmaceutical Journal URI: 10032801

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.